Thomson Medical Group Limited Overview
Thomson Medical Group is a mid-sized, controller-owned Southeast Asian private hospital group operating in Singapore, Malaysia and Vietnam, with 816 licensed beds across three hospitals at 30 June 2026. Its franchise originates in Thomson Medical Centre, a 187-bed Singapore maternity and paediatric hospital that the company says delivers more than one in five Singapore births, supported by 36 clinics and centres. Around this core it has built a Bursa-listed Malaysian tertiary hospital platform (TMC Life Sciences, 70.1%-owned, anchored by 399-bed Thomson Hospital Kota Damansara and Malaysia's leading fertility chain) and, since December 2023, a JCI-accredited Vietnamese tertiary hospital (FV Hospital, Ho Chi Minh City). The investment case combines a defensive women's-and-children's brand being broadened into multi-specialty care with a large optionality asset: 26 acres of freehold waterfront land in Johor Bahru earmarked for the RM18 billion Johor Bay healthcare-led masterplan. The offsetting reality is high leverage (net debt/adjusted EBITDA of 12.1x) and three consecutive years of goodwill-driven losses or earnings compression.
What the company does
TMG is an investment holding company whose subsidiaries operate hospitals, specialist clinics and ancillary healthcare services. Its FY2026 results announcement describes the company's own principal activities as investments, investment holding and strategic investments, and those of its subsidiaries as operating hospitals and clinics and providing healthcare services. It reports four segments: Singapore, Malaysia and Vietnam (each comprising hospital and specialised services) and Investment Holdings (the Johor land bank held as investment and development property, and the group's central debt).
Company's own description (FY2026 press release, paraphrased)
The company presents itself as one of Southeast Asia's leading listed healthcare providers with operations in Singapore, Malaysia and Vietnam. In Singapore, Thomson Medical (founded 1979) offers women's health, fertility, paediatrics and specialist care, anchored by Thomson Medical Centre, close to 40 specialist clinics and facilities, and a 24/7 Urgent Care Centre. From its obstetrics, gynaecology, paediatrics and assisted-reproduction roots it now extends to oncology, orthopaedics, ENT, general surgery, health screening, diagnostic imaging, dentistry, specialist dermatology and Traditional Chinese Medicine. In Malaysia it operates through Bursa-listed TMC Life Sciences Berhad (Thomson Hospital Kota Damansara and TMC Fertility Centre) and owns the proposed Thomson Hospital Iskandariah in Johor Bahru. It also owns freehold waterfront land in Johor Bahru city centre for an integrated masterplan. In Vietnam, FV Hospital covers more than 30 specialties and operates the American Chiropractic Clinic network of three clinics.
Business and revenue model
| Revenue line (FY2026) | SGD Mn | % of revenue | Nature | Source |
|---|---|---|---|---|
| Rendering of services, including sale of goods | 415.5 | 98.9 | Fee-for-service hospital and clinic billing (inpatient, day surgery, outpatient, diagnostics, pharmacy) | FY2026 Note 5 |
| Rental income | 4.6 | 1.1 | Leasing of medical suites/space to tenant specialists and others | FY2026 Note 5 |
| Total | 420.1 | 100.0 | — | — |
| Recognised at a point in time | 409.5 | 97.5 | Episodic care | FY2026 Note 5 |
| Recognised over time | 10.6 | 2.5 | Packages (e.g., maternity, health-screening, fertility programmes) | FY2026 Note 5 |
The model is almost entirely service revenue; there is no meaningful product, subscription or licensing income. Two operating-model features are distinctive. First, in Singapore TMC runs a "tenant specialist" model in which independent obstetricians, paediatricians and other specialists practise from the hospital and its clinics while TMG captures facility, nursing, theatre, diagnostic and pharmacy revenue. Second, under Group CEO Dr Melvin Heng, TMG is using commercially incentivised partnerships with specialist groups (OncoCare in Malaysia and Singapore; NVTS Specialists in Singapore day surgery) rather than buying physician practices outright, an approach he described in a 2026 Edge Singapore interview as keeping doctors aligned rather than "cashed out".
Value-chain position, customers and end-markets
TMG sits at the provider layer: it owns and operates licensed hospital infrastructure, employs nursing and allied health staff, and contracts or hosts physicians. Upstream it buys drugs and consumables (S$110.2M in FY2026, rising with oncology volumes); downstream it is paid by self-pay patients, private insurers and third-party administrators, corporates, and (in Vietnam from 1 January 2026, per Vietnamese press) the national health-insurance scheme. Customer types include Singapore families (maternity, paediatrics, fertility), Malaysian domestic and medical-tourism patients (oncology, fertility, specialist surgery), and Ho Chi Minh City middle-class and expatriate patients plus regional patients from Cambodia, Laos and Myanmar.
Independent characterisation
TMG is best understood as three businesses of different quality joined by a levered holding company and a land bank. Singapore is a mature, high-margin (24.3% segment EBITDA margin in FY2026) maternity franchise whose volume base is shrinking with deliveries and whose growth now depends on pricing and specialty mix. Malaysia is the inflection story, with segment revenue up 19.0% and segment profit rising from S$0.9M to S$5.3M in FY2026 as oncology ramps. Vietnam is a quality asset bought at a full price (S$469.1M cash) whose goodwill has been written down twice (S$75.1M in FY2025, S$15.2M in FY2026). The holding layer carries S$998.2M of segment liabilities and absorbed S$43.9M of finance costs in FY2026, which is why the group reports losses despite all three operating segments being profitable at the segment level.
Strategy
Stated strategy themes (paraphrased from FY2026 briefing and results)
Management frames its strategy as a long-term plan set in motion in 2022 that is now showing through in operating performance, with the priority being to deepen the same model in each market and convert scale into earnings. The four stated focus areas for the year ahead are: building specialty depth; widening payor and cross-border access; improving utilisation and operating leverage; and maintaining disciplined capital allocation.
By country, the company's themes are: in Singapore, evolving from women's and children's health into a broader family-centred platform (general surgery, gastroenterology, ENT, orthopaedics), with broader payor access and pricing discipline lifting revenue intensity and theatre utilisation; in Malaysia, converting specialist expansion into earnings, led by oncology, with medical tourism as a key channel and Johor as the longer-term opportunity; in Vietnam, patient growth with capacity still to come through the H-wing expansion for oncology, diagnostics and advanced surgery.
Strategic initiatives in the last 24 months
| Initiative | Date | Description | Status | Source |
|---|---|---|---|---|
| Thomson OncoCare (Malaysia) | Sep 2024 / Nov 2024 | Oncology partnership at THKD; drove Malaysia revenue +19% in FY2026 | Operating | Bernama; FY2026 |
| TMC rejuvenation | FY2025 | Ground-floor rebuild, MRI suite, Urgent Care Centre | Completed | AR2025; Edge 2026 |
| Thomson OncoCare Cancer Centre at TMC | 2,025 | Oncology replicated in Singapore | Operating | Edge 2026 |
| FV H Building | Announced May 2025 | US$45M building, +6,700 sqm, oncology/IVF/GI/dialysis | Under construction | Le Petit Journal |
| FV grounds expansion | Late 2025 | Permission for additional 10,000 sqm; planned centres of excellence in oncology, IVF, GI, cardiology | Planning | Edge 2026 |
| Johor Bay | 25 Aug 2025 | RM18bn GDV healthcare-led masterplan on 26 acres; phase 1 hospital plus 47-storey residence | Seeking development partners | EdgeProp; Edge 2026 |
| Payor broadening | FY2026 | Reduced corporate discounts; deeper insurer, TPA, broker and corporate relationships in Singapore; FV accepts national health insurance (Jan 2026) | Ongoing | FY2026 announcement; Vietnamese press |
| Aspire Surgery Centre | Apr–Aug 2026 | 40% day-surgery JV with NVTS Specialists (S$1.12M) | Formed | FY2026 Note 17 |
| Digital transformation | FY2024–FY2026 | EMR rollout in Singapore; in-house software teams; higher digital spend cited as an opex driver in FY2026 | Ongoing | FY2026 announcement; Edge 2026 |
| Clinical capability upgrades at THKD | FY2026 | HIFU, HIPEC, CO2 laser, EUS, 3D imaging; MSQH 4-year accreditation, BFHI, ISO 15189 | Completed | FY2026 Briefing |
| Board refresh | Feb 2026 | Property-experienced chairman | Completed | SGX |
| Sustainability | FY2024–FY2025 | TCFD-aligned climate reporting; net-zero 2050 commitment | Ongoing | AR2024/AR2025 summaries |
Guidance and targets
TMG does not publish numeric financial targets. Its FY2026 announcement states that the group expects to continue incurring losses over the next 12 months as it continues investment, expansion and transformation. No cost-saving programme with quantified targets, no leverage target and no dividend resumption timetable have been disclosed. Management has linked Johor Bay to addressing gearing (FY2025 Press Release), but has not quantified expected proceeds or timing.
Products & Services
TMG sells healthcare services rather than products. Pricing is fee-for-service; package pricing is used for maternity, screening and fertility programmes (evidenced by the "over time" revenue line), but list prices are not disclosed in filings. The catalogue below is organised by segment.
Singapore (Thomson Medical Pte Ltd)
| Offering | Description and capabilities | Target customer | Launch / latest | Source |
|---|---|---|---|---|
| Thomson Medical Centre (TMC) | Flagship private hospital, 187 licensed beds (178 operational), O&G and paediatric focus; surgical operations, diagnostic imaging, pharmacy, laboratory; company states it accounts for more than 20% of Singapore births. FY2026 bed occupancy 49.4% | Expectant mothers, families | Opened 1979; ground-floor rebuild with new lobby, relocated pharmacy and blood bank completed under current CEO; official reopening in FY2025 | FY2026 Briefing; Edge interview 2026 |
| 24-hour Urgent Care Centre | Round-the-clock care for non-life-threatening conditions staffed by doctors and nurses | Families, walk-in patients | FY2025 | FY2026 Briefing; AR2025 summary |
| MRI Suite | First MRI within TMC, complementing X-ray and ultrasound at Thomson Diagnostic Imaging Centre (TDIC) | Referred patients | FY2025 | FY2026 Briefing |
| Thomson Diagnostic Imaging Centre | X-ray and ultrasound services | Inpatients, outpatients | Existing | FY2026 Briefing |
| Thomson Women's Clinics | Network of O&G clinics across Singapore heartland and central locations | Women | Existing; network of 36 clinics and centres (vs 16 in 2010) | FY2026 Briefing |
| Thomson Fertility Centre / egg freezing | Assisted reproduction; elective egg freezing following July 2023 legalisation, with the company claiming one of the highest private-sector case counts | Couples, women preserving fertility | Egg freezing from FY2024 | FY2024 Results Announcement |
| Thomson Paediatric Centre / paediatric clinics | Outpatient paediatric care | Children | Existing | FY2026 Briefing |
| Thomson Specialists (Paragon) | Multi-specialty centre at Paragon Medical Centre (rebranded from Thomson Wellth) | Affluent patients | Rebrand during FY2023 | AR2023 |
| Thomson Breast Centre; Thomson Surgical Centre | One-stop breast centre at TMC; surgical centre | Women; surgical patients | 2,019 | 2Q2019 press release |
| Thomson OncoCare Cancer Centre (at TMC) | Oncology centre set up by OncoCare at TMC | Cancer patients | 2,025 | Edge interview 2026 |
| Gynaecological oncology, health screening, dentistry, specialist dermatology, TCM | Ancillary specialist services | Families | Existing | FY2025 Press Release |
| New specialties: orthopaedics, ENT, general surgery, gastroenterology | Complementary family-focused surgery to lift theatre utilisation | Families | FY2025–FY2026 | FY2026 Briefing |
| Aspire Surgery Centre (40% associate) | Day-surgery operating theatre with NVTS Specialists | Specialist-referred patients | Incorporated Apr 2026; SHA Aug 2026 | FY2026 Note 17 |
| Locations | Novena Medical Centre, Novena Specialist Centre, Orchard, Tiong Bahru, Katong, Serangoon, Tampines, Punggol, Sengkang, Sembawang, Woodleigh, Choa Chu Kang, Bukit Batok, Jurong East, United Square | — | At 30 Jun 2026 | FY2026 Briefing map |
Malaysia (TMC Life Sciences Berhad)
| Offering | Description and capabilities | Target customer | Launch / latest | Source |
|---|---|---|---|---|
| Thomson Hospital Kota Damansara (THKD) | Tertiary multi-disciplinary hospital, 399 licensed beds (327 operational), expandable to 554; FY2026 occupancy 52.4% | Klang Valley residents; medical tourists | Est. 2008; expansion licensed 30 Mar 2022 | FY2026 Briefing |
| Thomson OncoCare / Oncology Centre | Partnership with OncoCare Medical Malaysia offering precision oncology, immunotherapy, targeted therapy, tumour boards; drives most of Malaysia's FY2026 growth | Cancer patients incl. foreign | Agreement 6 Sep 2024; operations Nov 2024 | Bernama; FY2026 Results |
| Urology/oncology technology | HIFU, laser TURP, targeted TRUS biopsy | Prostate cancer/BPH patients | FY2026 | FY2026 Briefing |
| Colorectal oncology | HIPEC (tumour removal with heated chemotherapy) | Advanced abdominal cancer | FY2026 | FY2026 Briefing |
| ENT | CO2 laser systems; first in Malaysia to offer ENT, head and neck CO2 laser treatment | ENT patients | FY2026 | FY2026 Briefing |
| Gastroenterology and hepatology | EUS and liver elastography | GI/liver patients | FY2026 | FY2026 Briefing |
| Orthopaedic and spine | 3D image intensifier | Surgical patients | FY2026 | FY2026 Briefing |
| TMC Fertility Centre | Four fertility centres (incl. Kota Damansara, Puchong, Ipoh, Johor Bahru); company describes it as Malaysia's industry leader in assisted reproduction | Couples | New entities for Ipoh, Penang, South incorporated FY2024 | FY2024 & FY2026 announcements |
| Thomson Specialist Clinics (Kepong) and other clinics | 3 other clinics and centres | Outpatients | FY2024 | FY2024 announcement |
| Laboratory | First private hospital in Malaysia with total laboratory automation; MS ISO/IEC 15189 accredited | Hospital-wide | FY2026 accreditation | FY2026 Briefing |
| Thomson Hospital Iskandariah (planned) | Planned hospital approx. 1km from Johor CIQ; briefing shows 500 beds and 400 medical suites. CEO interview (2026) instead cites a hospital of about 300-plus beds at the masterplan's centre; discrepancy noted | Johor and Singapore cross-border patients | Under planning; FSMOne (Sep 2025) reports construction slated for early 2026 and operations by 2030 | FY2026 Briefing; Edge 2026; FSMOne |
Vietnam (Far East Medical Vietnam Ltd)
| Offering | Description and capabilities | Target customer | Launch / latest | Source |
|---|---|---|---|---|
| FV Hospital (District 7, HCMC) | Multi-specialty private tertiary hospital with 30+ specialties; first JCI-accredited hospital in South Vietnam, four consecutive JCI accreditations; GFA 26,300 sqm; over 1,600 staff and over 200 doctors (briefing). Licensed beds 230, operational 186, occupancy 49.8% | HCMC/Mekong Delta middle class, expatriates, CLM region | Founded 2003 | FY2026 Briefing |
| Centres of excellence | Oncology, orthopaedics, cardiology, maternity, ophthalmology (incl. complex corneal transplants), gastroenterology | Complex-care patients | Ongoing | FY2026 Briefing; Edge 2026 |
| Thoracic surgery centre | Positioned as the region's first, serving Cambodia, Vietnam, Laos, Myanmar | Regional patients | Announced Aug 2024 | FY2024 Results Announcement |
| H Building expansion | US$45M new building adding 6,700 sqm (above ground) for oncology, IVF, gastroenterology day-hospital endoscopy, dialysis; total campus to reach 37,500 sqm; further permission for 10,000 sqm of grounds in late 2025 | Specialist patients | Announced May 2025; in construction | Le Petit Journal; Edge 2026; Bao Phap Luat |
| American Chiropractic Clinic (ACC) | Three chiropractic and sports-medicine clinics (District 5 and District 1 HCMC; Hanoi) | Musculoskeletal patients | Acquired with FEMVN | FY2026 Briefing |
| FV Saigon Clinic | Outpatient clinic in central HCMC | Outpatients | Pre-acquisition | TMG release, 21 Dec 2023 |
| National health-insurance acceptance | Applied across outpatient, inpatient and emergency services from 1 Jan 2026 (Vietnamese press; not confirmed in TMG filings) | Insured mass-market patients | Jan 2026 | Bao Phap Luat |
Investment Holdings / Real estate
| Offering | Description | Status | Source |
|---|---|---|---|
| Johor Bay masterplan | 26-acre (10.52ha) freehold waterfront site in JB city centre within the JS-SEZ, 1.2km from the Bukit Chagar RTS station; healthcare nucleus (hospital, specialist suites, aged-care living) plus luxury residences, five-star hotel, commercial-lifestyle precincts; phase 1 comprises Thomson Hospital Iskandariah and a 47-storey residential tower | Launched 25 Aug 2025; GDV RM18bn (approx. US$4.3bn). The 2026 CEO interview cites a projected GDV of S$5.5bn; management in advanced talks with development partners | EdgeProp; Forbes; Edge 2026 |
Financial Narrative
All figures S$M, fiscal years ended 30 June, audited, from TMG FY2023, FY2024 and FY2026 Results Announcements (each year's figures taken from that year's or the following year's audited statements). FY2024 balance-sheet equity was later restated from 578.2 to 577.0 upon finalisation of the FEMVN purchase price allocation (FY2025 statement of changes in equity opens at 577.0).
Income statement
Adjusted EBITDA definitions: FY2023–FY2024 exclude one-off transactions and non-recurring costs (FEMVN deal costs and FX loss); FY2025 excludes S$75.1M goodwill impairment and S$54.6M reversal of impairment on development and investment properties; FY2026 excludes S$15.2M goodwill impairment.
Margins and growth (computed)
Revenue CAGR FY2022–FY2026 (computed): 5.9%. Company-defined "core revenue" (excluding COVID projects) grew 73% from S$228.5M in FY2021 to S$394.7M in FY2025 (FY2025 Press Release).
Commentary. The five-year record divides into two regimes. FY2022–FY2023 margins were inflated by COVID-era government project income (vaccination centres, Transitional Care Facilities) and Job Support Scheme grants; adjusted EBITDA margins above 30% were not structural. FY2024 was the hinge: COVID income ended in December 2023 while FEMVN was consolidated for six months, and acquisition borrowing lifted finance costs by 69% to S$51.6M. FY2025 was the trough: FEMVN's full-year consolidation dragged margins down (Vietnam's EBITDA margin is roughly 10 points below Singapore's), Malaysia suffered from terminated insurer contracts and pricing adjustments, and a S$75.1M goodwill impairment produced the first loss since FY2020. FY2026 shows tentative recovery: adjusted EBITDA grew 9.9%, faster than revenue, finance costs fell S$10.5M as SORA-linked loan rates eased, and the loss narrowed 40.8%. The falling gross-margin proxy (83.4% to 73.8%) reflects mix shift toward drug-intensive oncology and lower-priced Vietnamese care rather than pricing weakness; Singapore inpatient average bill size rose 21.8% in FY2026 alone.
Balance sheet
Goodwill by CGU at 30 Jun 2026: TMPL S$379.8M; TMCLS S$42.9M; BBWF S$61.4M; FEMVN S$275.3M (down from S$406.4M provisional in FY2024). The FY2024 goodwill figure of S$880.5M includes provisional FEMVN goodwill before purchase price allocation reclassified part to identifiable intangibles (brand name rose from S$3.9M to S$25.8M).
Commentary. The FEMVN purchase (S$469.1M cash; S$460.0M net of cash acquired) was funded overwhelmingly by debt and cash: gross borrowings rose S$358M in FY2024 and cash fell S$119M, taking net debt from S$461M to S$939M. Equity has since eroded by S$52.7M through losses and goodwill write-downs while net debt continued to drift up to S$990.7M, so the balance sheet has de-levered by nothing since the deal. Goodwill and intangibles equal 151% of total equity at 30 Jun 2026, meaning tangible equity is negative on a consolidated basis. The Johor land is carried at cost less impairment (investment property S$144.0M; development property S$135.5M; BBWF PPE S$89.8M); management states it is "well undervalued" on the books (Edge interview, 2026), and the investment property's disclosed fair-value input is MYR900 per sq ft.
Cash flow
Commentary. Free cash flow before interest has remained positive throughout, but it no longer covers interest and lease payments. In FY2026 FCF of S$51.0M compared with S$58.5M of interest plus lease principal, producing the S$11.4M net cash outflow. Capex was cut sharply in FY2026 (S$15.3M versus S$22.6M), which supports near-term cash but sits awkwardly with funding the FV H Building (US$45M) and any Johor equity contribution. Operating cash flow recovered 17.4% in FY2026, aided by tax paid falling from S$7.6M to S$2.0M.
Ratios (computed unless stated)
ROIC uses a 17% notional tax rate and invested capital defined as gross borrowings plus total equity less cash. The FY2022 ROE denominator uses opening equity at 1 July 2021 of S$489.8M. A full cash conversion cycle is not computable because TMG does not separately disclose trade payables days for the group; receivable days are shown as the closest available proxy. Company-reported net-debt-to-adjusted-EBITDA is 11.2x (Jun 2024), 13.1x (Jun 2025) and 12.1x (Jun 2026) per the FY2026 Results Briefing; the analyst's FY2026 figure of 12.0x differs only because the company includes S$3.3M of finance lease in debt.
Commentary on ratios. Every leverage and coverage metric deteriorated step-wise with the Vietnam deal and has improved only marginally since. The critical number is adjusted EBITDA cover of finance costs at 1.68x; EBIT does not cover interest (0.53x). Absent asset monetisation at Johor Bay, de-levering depends on EBITDA growth: holding net debt flat, adjusted EBITDA would need to reach roughly S$165M (double FY2026) to bring net debt/EBITDA to 6x.
Half-year progression
1H FY2026 adjusted EBITDA is derived (FY2026 S$82.5M less 2H S$43.6M). The 2H losses in both years include the annual goodwill impairment test charge.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Jurisdiction | Role | Ownership | Source |
|---|---|---|---|---|
Thomson Medical Group Limited | Singapore | Listed holding company; issuer of MTNs | — | Filings |
Sasteria Pte Ltd | Singapore | Intermediate holding company (penultimate holder of TMCLS) | 100% | TMCLS FY2026 directors' report |
Thomson Medical Pte Ltd (TMPL) | Singapore | Owns and operates Thomson Medical Centre and Singapore clinics | 100% | FY2026 Note 17 |
Sasteria (M) Pte Ltd | Singapore | Immediate holding company of TMCLS | 100% | TMCLS FY2026 directors' report |
TMC Life Sciences Berhad (TMCLS) | Malaysia (Bursa) | Operates THKD and TMC Fertility | approx. 70.1% (1,221,638,155 shares) | Simply Wall St shareholder register |
BB Waterfront Sdn Bhd (BBWF) | Malaysia | Wholly owned subsidiary of TMCLS that owns the Thomson Iskandar / Thomson Hospital Iskandariah site | 100% of TMCLS | FY2026 Note 11 |
Sasteria (VN) Pte Ltd; FVH Singapore Pte Ltd | Singapore | Holding vehicles for Vietnam (incorporated June 2023) | 100% | FY2023 Results Announcement |
Far East Medical Vietnam Ltd (FEMVN) | Vietnam | Operates FV Hospital and ACC clinics | 100% | FY2024 Note 13 |
Aspire Surgery Centre Pte Ltd | Singapore | Day-surgery operating theatre (with NVTS Specialists) | 40% associate (incorporated 24 Apr 2026) | FY2026 announcement |
Thomson X Pte Ltd | Singapore | Health-tech venture vehicle | 100% (per director listings) | GlobalData; 2021 press |
Segment Overview
| Segment | Contents | Key assets |
|---|---|---|
Singapore | Hospital and specialised services in Singapore | Thomson Medical Centre (187 licensed beds), 36 clinics and centres, Thomson Diagnostic Imaging Centre, MRI Suite, 24-hour Urgent Care Centre, fertility, paediatric, women's, TCM, dental, dermatology clinics |
Malaysia | Hospital and specialised services in Malaysia via TMCLS | THKD (399 licensed beds, 554 maximum capacity), Oncology Centre, 4 TMC fertility centres, 3 other clinics |
Vietnam | Hospital and specialised services in Vietnam via FEMVN | FV Hospital, District 7, HCMC (230 licensed beds); 3 American Chiropractic Clinics (District 5, District 1 HCMC; Hanoi) |
Investment Holdings | Johor investment property and development property, holding-company financing | Freehold land in Iskandar Development Region (investment property S$144.0M, development property S$135.5M, BBWF land in PPE S$89.8M at 30 Jun 2026) |
Revenue by Segment
| Segment (SGD Mn, FY ends 30 Jun) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Singapore revenue | 260.4 | 200.2 | 190.4 | 192.9 |
Malaysia revenue | 95.0 | 100.1 | 105.3 | 125.3 |
Vietnam revenue | 0 | 50.4 | 98.4 | 101.3 |
Investment Holdings revenue | 0.4 | 0.4 | 0.5 | 0.5 |
Group revenue | 355.8 | 351.2 | 394.7 | 420.1 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Margins & Growth (%) and Revenue by Segment (%)
| Metric (%) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Singapore revenue YoY growth | -23.1 | -4.9 | 1.3 |
Malaysia revenue YoY growth | 5.5 | 5.2 | 19.0 |
Vietnam revenue YoY growth | — | 95.3 | 2.9 |
Singapore share of group revenue | 57.0 | 48.2 | 45.9 |
Malaysia share of group revenue | 28.5 | 26.7 | 29.8 |
Vietnam share of group revenue | 14.4 | 24.9 | 24.1 |
Results by Segment
| Segment metric (SGD Mn) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Singapore segment profit after finance costs | 60.2 | 28.6 | 24.9 | 22.6 |
Malaysia segment profit | 11.7 | 11.5 | 0.9 | 5.3 |
Vietnam segment profit | 0 | 4.1 | 2.7 | 3.0 |
Investment Holdings segment loss | -30.8 | -24.7 | -75.5 | -58.6 |
Group profit/(loss) for the year | 41.1 | 19.5 | -47.0 | -27.8 |
Segment EBITDA (SGD Mn, company-reported)
| Segment EBITDA (SGD Mn, company-reported) | FY2025 | FY2026 |
|---|---|---|
Singapore EBITDA | 48.5 | 46.8 |
Malaysia EBITDA | 14.0 | 21.4 |
Vietnam EBITDA | 15.0 | 14.8 |
Investment Holdings EBITDA (reported, incl. impairments/reversals) | -22.9 | -15.7 |
Investment Holdings adjusted EBITDA | -2.4 | -0.5 |
Group EBITDA | 54.6 | 67.3 |
Group adjusted EBITDA | 75.1 | 82.5 |
Segment margin (%)
| Segment margin (%) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Singapore EBITDA margin (company) | — | 25.5 | 24.3 |
Malaysia EBITDA margin (company) | — | 13.3 | 17.0 |
Vietnam EBITDA margin (company) | — | 15.3 | 14.6 |
Singapore segment-profit margin (computed) | 14.3 | 13.1 | 11.7 |
Malaysia segment-profit margin (computed) | 11.5 | 0.9 | 4.3 |
Vietnam segment-profit margin (computed) | 8.1 | 2.7 | 2.9 |
Revenue by Segment (FY2022–FY2023)
| Old segment (SGD Mn) | FY2022 | FY2023 |
|---|---|---|
Hospital Services revenue | 162.5 | 186.3 |
Specialised Services revenue | 170.9 | 169.1 |
Investment Holdings revenue | 0.3 | 0.4 |
Hospital Services profit before tax | 37.1 | 39.1 |
Specialised Services profit before tax | 56.8 | 46.5 |
Investment Holdings loss before tax | -24.7 | -30.3 |
Segment Overview — Singapore
| Segment | Assets | Liabilities | Additions to non-current assets |
|---|---|---|---|
Singapore | 673.4 | 147.1 | 24.1 |
Malaysia | 411.2 | 80.2 | 7.0 |
Vietnam | 365.5 | 23.3 | 10.6 |
Investment Holdings | 324.1 | 998.2 | 0.03 |
Group | 1,774.2 | 1,248.7 | 41.7 |
Income Statement and Per-Share Data
| Metric (SGD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue | 333.7 | 355.8 | 351.2 | 394.7 | 420.1 |
Other income | 9.8 | 5.6 | 31.5 | 60.9 | 6.5 |
Inventories and consumables used | 55.3 | 59.4 | 75.2 | 99.3 | 110.2 |
Gross profit proxy (revenue less consumables; not reported by TMG) | 278.4 | 296.4 | 275.9 | 295.3 | 309.9 |
Staff costs | 107.9 | 118.0 | 121.8 | 135.5 | 140.9 |
Depreciation and amortisation | 17.9 | 21.1 | 27.5 | 38.7 | 41.0 |
Other operating expenses (incl. impairments) | 70.5 | 80.7 | 83.2 | 166.1 | 108.2 |
Results from operating activities (EBIT) | 91.8 | 82.3 | 75.0 | 15.9 | 26.3 |
EBITDA (company-reported) | 109.7 | 103.3 | 102.4 | 54.6 | 67.3 |
Adjusted EBITDA (company) | 109.7 | 106.6 | 109.8 | 75.1 | 82.5 |
Finance income | 1.0 | 3.9 | 7.4 | 3.6 | 1.8 |
Finance costs | 23.5 | 30.5 | 51.6 | 59.7 | 49.2 |
Net finance costs | 22.5 | 26.6 | 44.2 | 56.0 | 47.4 |
Profit/(loss) before tax | 69.3 | 55.2 | 30.6 | -40.6 | -21.1 |
Income tax expense | 10.7 | 14.1 | 11.1 | 6.4 | 6.7 |
Profit/(loss) for the year | 58.6 | 41.1 | 19.5 | -47.0 | -27.8 |
Attributable to owners (PATMI) | 53.8 | 36.6 | 15.4 | -47.6 | -29.7 |
Attributable to non-controlling interests | 4.8 | 4.5 | 4.1 | 0.6 | 1.9 |
EPS basic (S$ cents) | 0.203 | 0.138 | 0.058 | -0.180 | -0.112 |
EPS diluted (S$ cents) | 0.203 | 0.138 | 0.058 | -0.180 | -0.112 |
Dividend per share declared for the year (S$ cents) | 0.115 | 0.040 | 0 | 0 | 0 |
Margin / growth (%)
| Margin / growth (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth YoY | — | 6.6 | -1.3 | 12.4 | 6.4 |
Gross margin proxy | 83.4 | 83.3 | 78.6 | 74.8 | 73.8 |
Operating (EBIT) margin | 27.5 | 23.1 | 21.3 | 4.0 | 6.3 |
EBITDA margin (reported) | 32.9 | 29.0 | 29.2 | 13.8 | 16.0 |
Adjusted EBITDA margin | 32.9 | 30.0 | 31.3 | 19.0 | 19.6 |
Pre-tax margin | 20.8 | 15.5 | 8.7 | -10.3 | -5.0 |
Net margin | 17.6 | 11.5 | 5.6 | -11.9 | -6.6 |
Balance Sheet and Per-Share Data
| Metric at 30 Jun (SGD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets | 1,364.9 | 1,447.8 | 1,807.4 | 1,784.6 | 1,774.2 |
Cash and short-term deposits | 161.6 | 286.6 | 167.3 | 124.2 | 113.1 |
Short-term borrowings | 227.7 | 12.1 | 189.2 | 163.9 | 201.8 |
Long-term borrowings | 401.4 | 735.6 | 917.0 | 942.0 | 902.0 |
Total borrowings (excl. leases) | 629.1 | 747.8 | 1,106.2 | 1,105.9 | 1,103.8 |
Lease liabilities | 13.8 | 15.0 | 15.2 | 15.7 | 26.2 |
Net debt (excl. leases, computed) | 467.5 | 461.2 | 938.9 | 981.7 | 990.7 |
Net debt (company, incl. finance lease) | — | — | 938.9 | 981.7 | 994.0 |
Total equity | 608.3 | 575.4 | 578.2 | 548.4 | 525.5 |
Equity attributable to owners | 531.7 | 499.4 | 500.9 | 470.9 | 442.4 |
Non-controlling interests | 76.7 | 76.0 | 77.3 | 77.5 | 83.1 |
Goodwill | 483.4 | 474.8 | 880.5 | 788.1 | 759.3 |
Total intangible assets (incl. goodwill) | 484.1 | 481.6 | 895.5 | 825.0 | 791.5 |
Current assets | 320.5 | 440.9 | 316.8 | 319.5 | 323.7 |
Current liabilities | 338.5 | 120.0 | 292.1 | 268.8 | 311.0 |
Working capital (computed) | -18.0 | 320.8 | 24.7 | 50.8 | 12.7 |
NAV per share (S$ cents) | 2.30 | 2.18 | 2.19 | 2.07 | 1.99 |
Cash Flow
| Metric (SGD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow before working capital | 110.1 | 105.7 | 77.7 | 75.7 | 82.0 |
Net cash from operating activities | 92.8 | 88.6 | 83.4 | 60.4 | 71.0 |
Purchase of property and equipment (capex) | 27.8 | 11.2 | 26.9 | 22.6 | 15.3 |
Purchase of intangible assets | 0.4 | 1.6 | 3.5 | 4.1 | 4.7 |
Free cash flow (OCF less capex and intangibles, computed) | 64.7 | 75.8 | 53.0 | 33.8 | 51.0 |
Acquisition of subsidiary, net of cash | 0 | 0 | 460.0 | 0 | 0 |
Interest paid | 22.1 | 31.1 | 49.7 | 61.0 | 48.8 |
Lease principal paid | 6.4 | 6.6 | 7.5 | 8.8 | 9.7 |
Dividends paid to owners | 4.0 | 30.4 | 10.6 | 0 | 0 |
Dividends paid to NCI | 1.1 | 1.5 | 2.3 | 3.9 | 0.5 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Net borrowings drawn/(repaid) | 10.2 | 123.5 | 358.0 | -4.3 | -5.9 |
Net change in cash and equivalents | 39.9 | 129.4 | -125.3 | -37.9 | -11.4 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (PATMI / avg owners' equity, %) | 10.5 | 7.1 | 3.1 | -9.8 | -6.5 |
ROA (profit / avg total assets, %) | 4.3 | 2.9 | 1.2 | -2.6 | -1.6 |
ROIC (EBIT × 0.83 / avg invested capital, %) | 7.1 | 6.5 | 4.9 | 0.9 | 1.4 |
Current ratio (x) | 0.95 | 3.67 | 1.08 | 1.19 | 1.04 |
Gross debt / equity (x) | 1.03 | 1.30 | 1.91 | 2.02 | 2.10 |
Net debt / equity (x) | 0.77 | 0.80 | 1.62 | 1.79 | 1.89 |
Net debt / reported EBITDA (x) | 4.3 | 4.5 | 9.2 | 18.0 | 14.7 |
Net debt / adjusted EBITDA (x, company basis) | — | — | 11.2 | 13.1 | 12.1 |
EBITDA / finance costs (x) | 4.67 | 3.39 | 1.99 | 0.92 | 1.37 |
Adjusted EBITDA / finance costs (x) | 4.67 | 3.49 | 2.13 | 1.26 | 1.68 |
EBIT / finance costs (x) | 3.91 | 2.70 | 1.45 | 0.27 | 0.53 |
Asset turnover (revenue / avg assets, x) | 0.24 | 0.25 | 0.22 | 0.22 | 0.24 |
Receivable days (year-end receivables / revenue × 365) | 66 | 64 | 45 | 52 | 55 |
Income Statement
| Metric (SGD Mn) | 1H FY2025 | 2H FY2025 | 1H FY2026 | 2H FY2026 |
|---|---|---|---|---|
Revenue | 199.1 | 195.6 | 213.1 | 207.0 |
Profit/(loss) after tax | -12.6 | -34.4 | -9.1 | -18.7 |
EBITDA (reported) | — | 15.5 | — | 28.4 |
Adjusted EBITDA | — | 36.0 | 38.9 | 43.6 |
Revenue by Region
| Region (SGD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Singapore | 254.6 | 260.4 | 200.2 | 190.4 | 192.9 |
Malaysia | 79.1 | 95.4 | 100.5 | 105.8 | 125.9 |
Vietnam | 0 | 0 | 50.4 | 98.4 | 101.3 |
Total | 333.7 | 355.8 | 351.2 | 394.7 | 420.1 |
Geographic growth (%)
| Geographic growth (%) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Singapore YoY | 2.3 | -23.1 | -4.9 | 1.3 |
Malaysia YoY | 20.5 | 5.4 | 5.3 | 19.0 |
Vietnam YoY | — | — | 95.3 | 2.9 |
Revenue by Region (%)
| Geographic mix (% of revenue) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Singapore | 76.3 | 73.2 | 57.0 | 48.2 | 45.9 |
Malaysia | 23.7 | 26.8 | 28.6 | 26.8 | 30.0 |
Vietnam | 0 | 0 | 14.4 | 24.9 | 24.1 |
Revenue by Region — Singapore
| Region (SGD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Singapore | 594.6 | 596.0 | 603.5 | 609.7 | 612.2 |
Malaysia | 449.8 | 410.9 | 421.6 | 471.7 | 491.9 |
Vietnam | 0 | 0 | 465.4 | 383.6 | 346.4 |
Revenue by Region (%) and Revenue by Region (SGD)
| Statistic | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Licensed beds, Singapore | 187 | 187 | 187 |
Licensed beds, Malaysia | 373 | 403 | 399 |
Licensed beds, Vietnam | 230 | 230 | 230 |
Operational beds, Singapore | 178 | 178 | 178 |
Operational beds, Malaysia | 341 | 310 | 327 |
Operational beds, Vietnam | 198 | 188 | 186 |
Bed occupancy, Singapore (%) | 56.3 | 54.7 | 49.4 |
Bed occupancy, Malaysia (%) | 55.6 | 49.0 | 52.4 |
Bed occupancy, Vietnam (%) | 50.0 | 46.3 | 49.8 |
Inpatients, Singapore | 14,738 | 14,658 | 13,319 |
Inpatients, Malaysia | 24,512 | 21,072 | 18,659 |
Inpatients, Vietnam | 7,323 | 6,611 | 7,042 |
Outpatients, Singapore | 254,934 | 244,246 | 237,893 |
Outpatients, Malaysia | 188,567 | 201,596 | 210,094 |
Outpatients, Vietnam | 237,789 | 230,726 | 246,550 |
Inpatient avg bill, Singapore (SGD) | 5,503 | 6,318 | 7,696 |
Inpatient avg bill, Malaysia (ZAR Mn) | 9,992 | 10,779 | 12,065 |
Inpatient avg bill, Vietnam (USD) | 4,103 | 4,250 | 4,340 |
Outpatient avg bill, Singapore (SGD) | 331 | 355 | 387 |
Outpatient avg bill, Malaysia (ZAR Mn) | 428 | 551 | 752 |
Outpatient avg bill, Vietnam (USD) | 188 | 185 | 186 |
Share Price History
| Date | Price (SGD) | Context | Source |
|---|---|---|---|
8 Jun 2023 | 0.059 | FV talks confirmed | The Edge |
28 Aug 2023 | 0.058 | FY2023 results; down 27.5% YTD | The Edge |
19 Sep 2023 | 0.059 | Float breach | The Edge |
4 Apr 2024 | 0.054 | Float restored | The Edge |
26 Aug 2024 | 0.050 | FY2024 results | The Edge |
12 Feb 2025 | 0.044 | 1H FY2025 loss | The Edge |
25 Aug 2025 | 0.049 | Johor Bay launch; down 2% YTD | The Edge |
11 Feb 2026 | 0.062 | 1H FY2026; up about 55% over 12 months | The Edge |
6 Oct 2026 | 0.049 | Latest available quote | MarketInOut |
Valuation Multiples
| Multiple | TMG | Basis |
|---|---|---|
Market capitalisation | S$1.30bn | 26.44bn shares |
Enterprise value | approx. S$2.37bn | Market cap + net borrowings S$990.7M + NCI S$83.1M (excl. leases) |
P/E | Not meaningful (loss) | FY2026 EPS -0.112 cents |
EV/EBITDA (reported FY2026) | 35.2x | EBITDA S$67.3M |
EV/EBITDA (adjusted FY2026) | 28.7x | Adjusted EBITDA S$82.5M |
EV/Sales | 5.6x | Revenue S$420.1M |
P/B | 2.46x | NAV/share 1.99 cents |
Analyst Ratings & Targets
| Broker | Date | Rating | Target (SGD) | Note | Source |
|---|---|---|---|---|---|
Phillip Securities (Paul Chew) | 11 Sep 2026 | BUY (upgraded on share price weakness) | 0.071 | FY26 revenue and EBITDA at 97%/98% of forecast; FY27e unchanged | POEMS |
Phillip Securities | 25 Feb 2026 | Not stated in source | — | Cut FY26 EBITDA estimate 17% to S$84M | POEMS |
Maybank Securities (Eric Ong) | Aug 2024 | BUY | 0.06 (from 0.08) | Called FY2025 a transitional year | The Edge |
DBS (unrated note) | c. 2024 | Unrated | — | Described TMG as a "diamond in the rough" | The Edge tag listing |
Dividend (S$ cents per share, by fiscal year declared)
| Dividend (S$ cents per share, by fiscal year declared) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per share | 0.115 | 0.040 | 0 | 0 | 0 |
Cash dividends paid to owners in year (SGD Mn) | 4.0 | 30.4 | 10.6 | 0 | 0 |
Capital Instruments
| Instrument | Coupon | Maturity | Principal (SGD Mn) |
|---|---|---|---|
Series 004 notes (S$155M + S$20M tap) | 5.25% | May 2027 | 175 |
Series 003 notes (S$120M + S$30M + S$25M) | 5.50% | May 2028 | 175 |
Series 005 notes (S$160M + S$25M tap) | 4.65% | Oct 2029 | 185 |
Secured bank loans – current | Floating (largely) | Within 12 months | 26.8 |
Secured bank loans – non-current | Floating (largely) | Beyond 12 months | 542.5 |
Lease liabilities | — | Various | 26.2 |
Maturity bucket (SGD Mn, carrying) | FY2027 | FY2028 | FY2029 |
Medium-term notes maturing | 175 | 175 | 0 |
Analyst Conclusions
Management guidance
TMG guides only qualitatively: it expects continued losses over the next 12 months while investment, expansion and transformation continue; it sees growth opportunities in private healthcare and medical tourism; and it will deepen insurer, TPA, corporate and broker relationships in Singapore, build on THKD's oncology and reproductive medicine platform in Malaysia while progressing Iskandariah, and expand FV's tertiary capability through the H Building (FY2026 Results Announcement, para 4).
Consensus
No formal consensus is published. Phillip Securities maintains FY2027 forecasts unchanged after FY2026 results and a S$0.071 target; its February 2026 FY2026 EBITDA estimate of S$84M versus actual adjusted EBITDA of S$82.5M indicates the broker's figures are tracking adjusted EBITDA. Simply Wall St's 2024 snapshot showed analysts forecasting about 6.9% annual revenue growth over three years, consistent with the FY2022–FY2026 CAGR of 5.9%.
Bull case
-
Operating leverage is appearing. Adjusted EBITDA grew 9.9% on 6.4% revenue growth in FY2026, Malaysia segment EBITDA rose 52% to S$21.4M, and THKD still has 227 beds of licensed-to-maximum headroom. If Malaysia continues at FY2026's trajectory and Vietnam's H Building adds oncology and IVF capacity, adjusted EBITDA above S$100M within two to three years is plausible.
-
Johor Bay is a de-levering lever. A partner-funded development on 26 freehold acres with RM18bn GDV could crystallise value well above the roughly S$369M combined book value of the land, directly addressing net debt of S$994M, as management has explicitly linked the project to gearing.
-
Interest costs are falling. Net finance costs fell S$8.6M in FY2026; refinancing the S$175M 5.25% 2027 notes and repricing floating bank debt at lower rates would add several million dollars of pre-tax profit a year, helping close the gap from a S$21.1M pre-tax loss.
Bear case
-
The balance sheet leaves no margin for error. EBIT covers finance costs only 0.53x, free cash flow after interest and leases is negative, and S$201.8M of borrowings are current. Any payor shock similar to Malaysia's FY2025 contract losses or a rate rise would push leverage higher.
-
Vietnam may keep disappointing. The earn-out was missed, two impairments totalling S$90.3M have been taken, Vietnam's EBITDA margin is slipping (15.3% to 14.6%), national insurance adoption dilutes pricing, and the 14.4% discount rate still leaves S$275.3M of goodwill exposed.
-
Volume decline undermines the core. Group inpatients have fallen 16% in two years and Singapore occupancy is below 50%; price-led growth through average bill size cannot compound indefinitely against declining births and payor resistance.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | What to watch |
|---|---|---|
| FY2026 Annual Report and AGM | Oct 2026 (expected) | Director remuneration, risk section, sustainability data |
| Johor Bay development partner announcement | Undated | Structure (land sale, JV, lease), cash proceeds, use against debt |
| Refinancing of S$175M May 2027 notes | Before May 2027 | Coupon versus 5.25%; any new MTN tranche |
| 1H FY2027 results | Feb 2027 (expected) | Malaysia momentum, Singapore volumes under new CEO, Vietnam FX |
| FV H Building opening | — | Capacity, oncology/IVF launch |
| Permanent Singapore CEO appointment | Undisclosed | Leadership stability |
| Thomson Hospital Iskandariah construction start | FSMOne cited early 2026; status not confirmed | Capex funding source |
| Goodwill testing at 30 Jun 2027 | Aug 2027 | FEMVN discount-rate assumptions |
Analyst verdict
Thomson Medical Group is a good collection of healthcare assets trapped inside a stretched capital structure. Each operating segment is profitable, revenue intensity is rising in all three markets, and the Malaysian oncology build-out shows that management's partnership model can create earnings quickly and with little capital. The FY2026 results mark the first year since the FV acquisition in which adjusted EBITDA grew faster than revenue, operating cash flow rose, and losses narrowed materially. On an operating view, the turnaround narrative is credible.
The equity case, however, rests on what happens at the holding company. Net debt of almost S$1bn against S$82.5M of adjusted EBITDA means that nearly all of the operating improvement is still being consumed by interest, and shareholders have absorbed S$90.3M of goodwill write-downs on the Vietnam deal in two years. With EBIT covering interest roughly half a time, organic de-levering is slow; at the current pace, reaching a conventional 5–6x leverage ratio would take most of a decade. The decisive variable is therefore Johor Bay. If management lands a credible development partner and converts part of the land's latent value into cash, the market's premium multiple (about 29x adjusted EBITDA, roughly double IHH) becomes defensible. If the partnership drags, the valuation looks stretched for a loss-making, controller-dominated company with a 10% free float and no dividend.
For institutional investors, the equity is a special situation rather than a core healthcare holding: liquidity is thin, governance is concentrated, and outcomes are binary around the Johor transaction. The senior unsecured notes, by contrast, benefit from positive operating cash flow, spread maturities (2027, 2028, 2029) and asset backing from the land and hospitals, and appear to offer the better risk-adjusted exposure to the turnaround. Overall assessment: operationally improving, financially fragile, with valuation contingent on asset monetisation that has been announced but not yet delivered.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Independence | Tenure / appointment | Background | Age | Source |
|---|---|---|---|---|---|---|
Tan Sri Tong Kooi Ong | Chairman | Independent, Non-Executive | Since 1 Feb 2026 | Founder and chairman, The Edge Media Group; Executive Chairman, Avarga Ltd (SGX); appointed for property and capital-intensive development experience | 66 (GlobalData) | SGX 12 Jan 2026 |
Lim Wee Kiat (Kiat Lim) | Executive Vice-Chairman | Executive; son of controlling shareholder Lim Eng Hock | Director since Mar 2019; ED from Jan 2022; EVC from 1 Sep 2022 (FY2024 filing shows position from 1 Jan 2022; discrepancy noted) | Responsible for group growth strategy and M&A; former CEO of Thomson X; director of RSP Architects | 33 (FY2026 filing) | FY2023/FY2026 announcements |
Dr Heng Jun Li Melvin | Executive Director and Group CEO | Executive | Joined 2022; Group CEO by Aug 2023 | Former CEO and COO, Gleneagles Hospital (GlobalData); acting Group CEO of TMCLS 29 Jan 2024 to 10 Feb 2025 | 42 (GlobalData, dated) | GlobalData; Simply Wall St |
Wilson Sam | Executive Director and Group CFO | Executive | Since 15 Mar 2019 | Former SVP Investments, Kestrel Capital; B.Bus (Hons), Nanyang Technological University | 49 (GlobalData) | SGX 14 Mar 2019 |
Ong Pang Liang | Non-Executive Director | Non-independent (previously independent, on board since at least May 2019) | Approx. 7+ years | Not detailed in sources reviewed | — | SGX announcements |
Christina Teo Tze Wei | Non-Executive Director; Chair, NRC | Independent | Since 1 Jan 2022 | Not detailed in sources reviewed | — | SGX 1 Jan 2022 |
June Leong Lai Ling | Non-Executive Director; Chair, ARC | Independent | Since 1 Jan 2022 | Not detailed in sources reviewed | — | SGX 1 Jan 2022 |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Title | Since | Background | Source |
|---|---|---|---|---|
Cassandra Loh Wei Ning | Acting CEO, Thomson Medical Singapore, and Chief Commercial Officer | Acting CEO from 1 Jul 2026 | Senior roles at Intellect, Cigna Singapore (Lead, Health and Wellness), Parkway Pantai/IHH; MSc Communications Management, SMU | SGX 1 Jun 2026 |
Dr Jean-Marcel Guillon | Founder and CEO, FV Hospital | Founder (2003) | French physician; led FV through acquisition | TMG release Dec 2023; Le Petit Journal 2025 |
Dr Siva Kumaran Jayaraman | Acting CEO, Thomson Hospital Kota Damansara (as of Sep 2024) | 2024 | Not detailed | Bernama, Sep 2024 |
Seah Sin Yuen | Company Secretary | — | — | SGX filings 2026 |
Board & Management Changes
| Date | Change | Context | Source |
|---|---|---|---|
29 Jan 2024 | TMCLS Group CEO Wan Nadiah suspended; Dr Heng acting Group CEO of TMCLS | No reasons disclosed; outcome not publicly disclosed in sources reviewed | Bernama; The Edge |
10 Feb 2025 | Dr Heng ceases acting Group CEO role at TMCLS (remains non-executive director there) | — | Simply Wall St |
12 Jan 2026 | Tong Kooi Ong named Chairman from 1 Feb 2026, succeeding Ng Ser Miang (chairman since 2015) | Positioned for Johor Bay development phase | SGX |
1 Jun 2026 | Cassandra Loh named Acting CEO, Singapore, from 1 Jul 2026, succeeding Lee Suen Ming | Integrate commercial strategy with operations | SGX; Edge |
Major Shareholders
| Holder | Stake | Date | Source |
|---|---|---|---|
Lim Eng Hock (Peter Lim), direct and deemed | approx. 89.6% | Sep 2023 | The Edge Singapore |
Public float | 10.15% (2,685,007,380 shares, >8,000 holders) | 4 Apr 2024 | SGX announcement |
Ng Ser Miang (former chairman) | 0.059% | 2025 | Simply Wall St |
Another independent director (not named in source) | 0.057% | 2025 | Simply Wall St |
Competitive Landscape
Competitors by Segment
| Market / segment | Competitor | Type | Positioning vs TMG |
|---|---|---|---|
Singapore private hospitals | IHH Healthcare (Parkway Pantai: Mount Elizabeth, Mount Elizabeth Novena, Gleneagles, Parkway East) | Listed (Bursa/SGX) | Dominant premium tertiary operator; competes in O&G and paediatrics at Gleneagles/Mount Elizabeth |
Singapore | Raffles Medical Group (Raffles Hospital, clinics, insurance) | Listed (SGX) | Integrated provider-insurer; net-cash balance sheet |
Singapore maternity | KK Women's and Children's Hospital | Public (SingHealth) | Largest births volume; subsidised pricing |
Singapore private | Mount Alvernia Hospital; Farrer Park Hospital | Private / not-for-profit | Maternity and general private competitors |
Singapore specialist O&G | Singapore O&G Ltd and private specialist groups | Listed / private | Doctor-owned specialist clinics that refer to multiple hospitals |
Malaysia private hospitals | KPJ Healthcare | Listed (Bursa) | Largest Malaysian private network (30th hospital opened Mar 2025) |
Malaysia | IHH (Pantai, Gleneagles, Prince Court, Island Hospital) | Listed | Premium tertiary; strong medical tourism |
Malaysia | Sunway Healthcare | Private/listed group | Klang Valley tertiary competitor near Kota Damansara |
Johor | KPJ Johor hospitals; Gleneagles Medini; Regency Specialist Hospital; Columbia Asia Iskandar | Various | Incumbents for the planned Iskandariah hospital (CEO says nearest are 20–25 minutes away) |
Vietnam (HCMC) | Vinmec (Vingroup); Hoan My Medical Group; Tam Anh General Hospital; City International Hospital; Raffles Medical (Vietnam stake) | Private | Vinmec and Tam Anh scale fast; FV differentiated by JCI and French heritage |
Fertility (Malaysia/Singapore) | Independent IVF chains | Private | TMC Fertility claims Malaysian leadership |
Peer Comparison FY2026
| Metric | TMG (FY Jun 2026) | IHH Healthcare (FY Dec 2025) | Raffles Medical Group (FY Dec 2025) | KPJ Healthcare (FY Dec 2025) |
|---|---|---|---|---|
Revenue | S$420.1M | RM25.7bn reported (core RM26.2bn) | S$765.3M | RM4.26bn |
Revenue growth | 6.4% | 6% reported (18% core) | 1.8% | 9.2% |
EBITDA | S$67.3M reported; S$82.5M adjusted | RM5.6bn | S$135.0M | — |
EBITDA margin | 16.0% reported; 19.6% adjusted | approx. 21.8% | approx. 17.6% | — |
Net profit | -S$27.8M | PATMI ex-exceptionals RM2.3bn | PAT S$71.1M | PAT RM402M; net profit RM365.9M |
Net margin | -6.6% | approx. 8.8% (on core revenue) | 9.3% | approx. 9.4% (PAT) |
Balance sheet | Net debt S$994M; 12.1x adjusted EBITDA | — | Net cash S$261M | — |
“—” = not publicly disclosed.



